Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer

Mimura, Kaito; Shimomura, Akihiko; Gota, Tomoko; Ando, Kazunori; Kawamura, Yukino; Taniyama, Tomoko; Oishi, Hajime; Shimizu, Chikako

doi:10.1016/j.gore.2022.101084

Cited by 5 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mimura et al previously reported one MMR deficient patient who demonstrated objective response to the combination of with pembrolizumab and lenvatinib, after 22 days of therapy. ( Mimura et al, 2022 ) Our case series differs from that report in that more MMR deficient patients (n = 8) are reported and more courses of therapy (n = 126, range 1–39 cycles) were delivered. All but two of our patients initiated a lenvatinib below the FDA recommended dose of 20 mg/day.…”

Section: Discussioncontrasting

confidence: 63%

“…( Makker et al, 2019 ) Recently, Mimura et al reported a single dMMR endometrial cancer patient who progressed on single agent pembrolizumab but responded to the combination of pembrolizumab and lenvatinib. ( Mimura et al, 2022 ) However, in this case report only 22 days of therapy was administered before lenvatinib was discontinued because of a planned urinary diversion for a vesico-vaginal fistula. The overall response rate of Lenvatinib and pembrolizumab in Keynote 775 for dMMR patients was 41.5 % (95 % CI 29.4 – 54.4), supporting the potential activity of this regimen after standard chemotherapy.…”

Section: Introductionmentioning

confidence: 78%

See 1 more Smart Citation

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

Rose,

Feldman,

Podzielinski

et al. 2023

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 63%

Section: Introductionmentioning

confidence: 78%

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

Rose,

Feldman,

Podzielinski

et al. 2023

Gynecologic Oncology Reports

View full text Add to dashboard Cite

“…MMRd ECs have an intermediate prognosis. Numerous recent studies have focused on the immunotherapy for EC (17,18). And reports have demonstrated these two groups may benefit from immunotherapy (19,20).…”

Section: Main Body 21 Molecular Types Of Ecmentioning

confidence: 99%

Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype

Zhang,

Wang,

2023

Front. Oncol.

View full text Add to dashboard Cite

Endometrial cancer (EC) is one of the three most prevalent gynecological tumors affecting women and is the most prevalent gynecological malignancy in the developed world. Its incidence is rapidly increasing worldwide, mostly affecting postmenopausal women, whereas recently its prevalence has increased in younger people. EC is an immune gene disease and many studies have shown that the tumor-immunosuppressive microenvironment plays an important role in cancer progression. In recent years, findings regarding the immunosuppressive tumor microenvironment (ITME) of EC have included immune evasion mechanisms and immunotherapy, which are mostly immune checkpoint inhibitors (ICI) for EC. Recently studies on the ITME of different molecular types of EC have found that different molecular types may have different ITME. With the research on the immune microenvironment of EC, a new immunophenotype classification based on the immune microenvironment has been carried out in recent years. However, the impact of the ITME on EC remains unclear, and the immunophenotype of EC remains limited to the research stage. Our review describes recent findings regarding the ITME features of different EC molecular types. The advent of immunotherapy has brought hope for improved efficacy and prognosis in patients with advanced or recurrent EC. The efficacy and safety of ICIs combination therapy remains the focus of future research.

show abstract

“…According to the abstracts or titles of the articles during preliminary screening, 29 full-text papers and one meeting abstract were further scrutinized. Eleven publications were excluded because they did not provide data (Marcus et al, 2019;Rubinstein et al, 2019;Walsh et al, 2019;Hollebecque et al, 2021;Oaknin et al, 2021;Kristeleit et al, 2022;Liao et al, 2022;Mimura et al, 2022;Babar et al, 2023;Chow et al, 2023;…”

Section: Study Selectionmentioning

confidence: 99%

Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Han,

Guo,

Song

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Studies in recent years have shown that PD-1/PD-L1 inhibitors may have better effectiveness in patients with advanced or recurrent endometrial cancer. The effectiveness of PD-1/PD-L1 inhibitors is thought to be related to mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) classification in advanced or recurrent endometrial cancer. This study aims to evaluate the effectiveness of PD-1/PD-L1 inhibitors in patients classified as dMMR and pMMR.Methods: Medical databases were searched to identify relevant publications up to 30 November 2022. The primary outcome was comparison of objective response rate (ORR) in patients with dMMR and pMMR following treatment with PD-1/PD-L1 inhibitors; secondary outcomes were single-group ORR in patients with dMMR and in patients with pMMR, respectively.Results: Eleven studies were eligible for analysis and patients with advanced or recurrent endometrial cancer with molecular classification of dMMR had a higher total ORR than those with pMMR [odds ratio (OR), 7.70; 95% confidence interval (CI), 3.22–18.38; p < 0.01], with low evidence of between-study heterogeneity (I2 = 0%). The total ORR of patients with advanced or recurrent endometrial cancer with molecular type dMMR was 51.9% (95% CI, 33.6%–69.9%). The overall ORR of patients with advanced or recurrent endometrial cancer with molecular type pMMR was 16.1% (95% CI, 5.5%–30.3%).Conclusion: In our including studies, the patients with advanced or recurrent endometrial cancer with molecular types of dMMR and pMMR, following treatment with PD-1/PD-L1 inhibitors, the total ORR of patients with dMMR was higher than that of patients with pMMR. Since the current number of studies is not very large, it is possible that more studies will be published in the future and more precise results will be discussed further.

show abstract

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer

Cited by 5 publications

References 14 publications

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype

Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About